(Q37096987)

18 August 2017

MDM4 is a key therapeutic target in cutaneous melanoma (English)

1 reference

18 August 2017

Job de Lange

9

0 references

Hubing Shi

Hubing Shi

16

0 references

Ygal Haupt

Ygal Haupt

13

0 references

Jean-Christophe Marine

Jean-Christophe Marine

22

0 references

Ghanem Ghanem

19

Ghanem Ghanem

1 reference

18 August 2017

5

Michael Dewaele

1 reference

18 August 2017

2

Flavie Luciani

1 reference

18 August 2017

7

Aleksandra Zwolinska

1 reference

18 August 2017

Agnieszka Gembarska

1

1 reference

18 August 2017

Clare Fedele

3

1 reference

18 August 2017

Elisabeth A Russell

4

1 reference

18 August 2017

Stéphanie Villar

6

1 reference

18 August 2017

Sue Haupt

8

1 reference

18 August 2017

Dana Yip

10

1 reference

18 August 2017

James Goydos

11

1 reference

18 August 2017

Jody J Haigh

12

1 reference

18 August 2017

Lionel Larue

14

1 reference

18 August 2017

Aart Jochemsen

15

1 reference

18 August 2017

Gatien Moriceau

17

1 reference

18 August 2017

Roger S Lo

18

1 reference

18 August 2017

Mark Shackleton

20

1 reference

18 August 2017

Federico Bernal

21

1 reference

18 August 2017

language of work or name

English

0 references

publication date

22 July 2012

1 reference

18 August 2017

1 reference

18 August 2017

18

1 reference

18 August 2017

1239-1247

1 reference

18 August 2017

8

1 reference

describes a project that uses

18 August 2017

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC3744207/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

exact match

https://scigraph.springernature.com/pub.10.1038/nm.2863

0 references

cites work

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

A stapled p53 helix overcomes HDMX-mediated suppression of p53.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

29 September 2017

p53-based cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Role of Mdm4 in drug sensitivity of breast cancer cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Awakening guardian angels: drugging the p53 pathway

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Mdm2-mediated ubiquitylation: p53 and beyond.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Blinded by the Light: The Growing Complexity of p53

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Molecular pathogenesis of cutaneous melanocytic neoplasms

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Tumor-specific induction of apoptosis by a p53-reactivating compound.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Immunohistochemical characteristics of melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Restoration of p53 function leads to tumour regression in vivo

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

MDMX: from bench to bedside

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Modeling the therapeutic efficacy of p53 restoration in tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Malignant melanoma: genetics and therapeutics in the genomic era.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Hdmx modulates the outcome of p53 activation in human tumor cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Chemotherapy and targeted therapy combinations in advanced melanoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Mdmx as an essential regulator of p53 activity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

The role of B-RAF in melanoma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

The genetics of malignant melanoma: lessons from mouse and man.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Mutations of the BRAF gene in human cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Dual inactivation of RB and p53 pathways in RAS-induced melanomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

29 September 2017

Surfing the p53 network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Tumor spectrum analysis in p53-mutant mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

MDM2 and MDMX in cancer and development.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Differential roles of the pRb and Arf/p53 pathways in murine naevus and melanoma genesis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Amplification of CDK4 and MDM2 in malignant melanoma.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Mitogen-actived protein kinase activation is an early event in melanoma progression.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744207

Metastasizing Melanoma Formation Caused by Expression of Activated N-RasQ61Kon an INK4a-Deficient Background

3 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNM.2863

Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNM.2863

Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22820643

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22820643

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NM.2863

1 reference

18 August 2017

1 reference

18 August 2017

1 reference